Dose to pelvic lymph nodes during brachytherapy of locally advanced cervical cancer with 60Co HDR source

Brachytherapy ◽  
2021 ◽  
Author(s):  
Zahra Siavashpour ◽  
Mahdi Aghili ◽  
Shabnam Anjidani ◽  
Farid Zayeri ◽  
Mona Molekzadeh Moghani ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
Advanced Cervical Cancer ◽  
Pelvic Lymph Nodes ◽  
Locally Advanced Cervical Cancer

Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer

2020 ◽  
Vol 30 (11) ◽  
pp. 1705-1712
Author(s):  
Marjolein De Cuypere ◽  
Pierre Lovinfosse ◽  
Christine Gennigens ◽  
Johanne Hermesse ◽  
Ramon Rovira ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
Total Lesion Glycolysis ◽  
Recurrence Free Survival ◽  
Advanced Cervical Cancer ◽  
Free Survival ◽  
Pelvic Lymph Nodes ◽  
Locally Advanced Cervical Cancer ◽  
Pet Ct

ObjectiveThe aim of this study was to investigate the prognostic value of metabolic parameters obtained at pretreatment [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in patients with locally advanced cervical cancer. We hypothesize that these metabolic parameters could optimize the treatment decision and thus favor the outcome of patients suffering locally advanced cervical cancer.MethodsPatients with locally advanced cervical cancer underwent pretreatment PET/CT. Standard uptake values (maximum, mean, peak), metabolic tumor volume, and total lesion glycolysis were measured in the tumor and in the hypermetabolic pelvic lymph nodes. The relationship between clinical, pathological, and PET/CT metabolic parameters with recurrence-free survival and overall survival was assessed by Cox regression analysis.Results115 patients with a median age of 52 years (range 23–77) presented with locally advanced cervical cancer. After a mean follow-up of 33.0 months after initiation of therapy, 26 patients (22.6%) recurred of which 17 patients had distant metastasis; 18 (15.7%) patients died. Recurrence-free survival at 2 and 5 years was 79.2% and 72.2%, respectively. The total lesion glycolysis of the tumor and the delay between diagnosis and treatment were significantly associated with recurrence-free survival in the multivariate analysis (HR 1.00, p=0.004, and HR 2.04, p=0.02, respectively). Only the total lesion glycolysis of the tumor ≥373.54 (HR 2.49, 95% CI 1.15 to 5.38; p=0.02) remained significant after log rank testing. Overall survival at 2 and 5 years was 91.7% and 68.8%, respectively. The number of PET-positive pelvic lymph nodes was the only independent prognostic factor for overall survival in the multivariate analysis (HR 1.43, 95% CI 1.13 to 1.81; p=0.003).ConclusionTumor total lesion glycolysis and the number of positive pelvic lymph nodes on pretreatment PET/CT appear to be independent prognostic factors for recurrence and survival in patients with locally advanced cervical cancer. This may help to select patients who may benefit from therapeutic optimization and closer surveillance.

Dose to Pelvic Lymph Nodes with Image-Guided Brachytherapy in Patients with Locally Advanced Cervical Cancer

Brachytherapy ◽  
2014 ◽  
Vol 13 ◽  
pp. S63-S64 ◽  
Author(s):  
Sommer Rae Wild Nurkic ◽  
Flona Younan ◽  
Boon-Keng Kevin Teo ◽  
Lilie L. Lin
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
Advanced Cervical Cancer ◽  
Pelvic Lymph Nodes ◽  
Locally Advanced Cervical Cancer ◽  
Image Guided

The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer

Brachytherapy ◽  
2013 ◽  
Vol 12 (6) ◽  
pp. 555-559 ◽  
Author(s):  
Yongsook C. Lee ◽  
Dominique L. Rash ◽  
Robin L. Stern ◽  
Jyoti S. Mayadev
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Dose Rate ◽  
Locally Advanced ◽  
High Dose Rate ◽  
High Dose ◽  
Advanced Cervical Cancer ◽  
High Dose Rate Brachytherapy ◽  
Pelvic Lymph Nodes ◽  
Locally Advanced Cervical Cancer

scholarly journals Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Caryn Wujanto ◽  
Bok Ai Choo ◽  
David Tan ◽  
Arunachalam Ilancheran ◽  
Joseph Ng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
External Beam Radiation ◽  
External Beam ◽  
Advanced Cervical Cancer ◽  
Beam Radiation ◽  
Pelvic Lymph Nodes ◽  
Locally Advanced Cervical Cancer ◽  
Radiation Boost

THE ROLE OF SURGICAL STAGE IN COMBINATION THERAPY FOR PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

2019 ◽  
Vol 65 (5) ◽  
pp. 749-755
Author(s):  
D. Reyes Santyago ◽  
Anzhella Khadzhimba ◽  
M. Smirnova ◽  
Sergey Maksimov
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Combination Therapy ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
Advanced Cervical Cancer ◽  
Relapse Free Survival ◽  
Regional Lymph Nodes ◽  
Free Survival ◽  
Locally Advanced Cervical Cancer

Objective: to justify the expediency of the surgical stage as a part of the combination treatment for stage IIA-IIIB cervical cancer. Materials and methods. The study included 343 women with stage IIA-IIIB cervical cancer treated from 2013 to 2016 with mandatory follow-up for at least 2 years. Patients were divided into 2 groups. The first group included 214 patients who received a combination treatment. At the first stage, neoadjuvant chemoradiation therapy was performed (remote radiation therapy 5 days a week with radio modification with Cisplatin once a week at a dose of 40 mg/m2). After evaluating the effect, patients were subjected to surgical treatment or continued chemoradiotherapy. The second group (n = 129) received standard combined radiation therapy. Various schemes of combination and complex treatment and standard combined radiation therapy were evaluated using the indices of general and relapse-free survival. Results. The proposed scheme for the combination therapy for patients with locally advanced cervical cancer showed significantly higher survival rates at all the analyzed stages. For the combined treatment group with complete cytoreduction, the two-year overall and relapse-free survival with stage IIA is 94.1% vs. 82.4%, with IIB 90.8% vs. 80.3%, with IIB 87.5% vs. 75%, with IIB with metastatic lesion of regional lymph nodes 85% vs. 70%. For the second group, two-year overall and relapse-free survival with stage IIA 75% vs. 50%, with IIB 70.9% vs. 56.3%, with IIB 59.1% vs. 40.9%, with IIB with metastatic lesion of regional lymph nodes 62.2% and 40.5%. The advantages of this approach are most clearly seen within patients with metastatic lesions of regional lymph nodes (85% vs. 62% accordingly). Conclusion. Cytoreductive surgery in combination with the combination therapy allows to achieve a significant increase in overall and relapse-free survival for patients with locally advanced cervical cancer compared with standard treatment programs.

scholarly journals Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?

2014 ◽  
Vol 46 (4) ◽  
pp. 374-382 ◽  
Author(s):  
Seung Gyu Park ◽  
Jin Hee Kim ◽  
Young Kee Oh ◽  
Sang Jun Byun ◽  
Mi Young Kim ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Locally Advanced ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Prophylactic Irradiation

scholarly journals Novel approaches to diagnostic imaging of locally advanced cervical cancer

2019 ◽  
Vol 18 (2) ◽  
pp. 83-91
Author(s):  
N. G. Trukhacheva ◽  
I. G. Frolova ◽  
L. A. Kolomiets ◽  
A. V. Usova ◽  
E. G. Grigor’ev ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Diagnostic Imaging ◽  
Lymph Nodes ◽  
Fdg Pet ◽  
Locally Advanced ◽  
Radiotherapy Planning ◽  
Advanced Cervical Cancer ◽  
Contrast Enhanced Ultrasound ◽  
Locally Advanced Cervical Cancer ◽  
Contrast Enhanced

Cervical cancer is the second most common cancer after breast cancer and the third most common cause of cancer-related death followed by breast and lung cancers among women worldwide. advances in diagnostic imaging techniques provide better assessment of regional and distant cervical cancer metastasis. the use of contrast-enhanced ultrasound is a revolutionary imaging modality; it has several advantages over ct: no radiation exposure, nephrotoxicity, obtaining real-time information, relatively low cost and ease of use. currently, the contrast agent sonoVue is widely used in ultrasound imaging of liver, kidneys and pancreas lesions, as well as for closed abdominal injuries, multiple organ failure, breast and prostate cancers, etc. However, the role of contrast-enhanced ultrasound in gynecology is not clearly established. one of the most effective tools for the detection of locally advanced cervical cancer is mRi, which is used mainly to determine the local extent of the tumor. However, the use of functional mRitechniques has not yet been included in the standards. cervical cancer tissue has been found to show significantly lower diffusion-weighted imaging (dWi) values than normal cervical tissue, thus facilitating the detection of tumor and its spread. dWiis also used for differentiating changes after biopsy from residual tumor and for identifying small lymph nodes. the pEt/cttechnique combines the metabolic images of pEtwith anatomical images of ctand is more accurate than high resolution ctalone, especially in determining the involvement of regional lymph nodes and distant organs. 18-Fdg-pEt/cthas been successfully used for accurate staging of the disease (especially late stage), assessment of treatment response, radiotherapy planning, and detection of disease progression. in patients with advanced stages of cervical cancer (iiBiV stage), the 18-Fdg-pEt/ ctfindings can determine the treatment strategy in most cases, primarily due to high sensitivity (75–100 %) and specificity (87–100 %) in the detection of lymph node metastases.

Sign in / Sign up

Export Citation Format

Share Document